8 completed. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 4 | Completed 4 |
Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 24 | 2022-11-08 | 2023-05-18 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 64 | 2022-06-20 | 2023-03-06 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment - Healthy Volunteers, Atopic Dermatitis | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2011-05-01 | 2020-12-08 |
| Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients ROSE-010, Placebo - Irritable Bowel Syndrome Constipation Predominant | Phase 1 / Phase 2 | Completed | Mayo Clinic | 52 | 2010-01-01 | 2013-05-31 |
| Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome Pimecrolimus 1% Cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 3 | 2005-09-01 | 2019-08-14 |
Netherton Syndrome (6) · Cerebral Palsy (1) · Constipation (1) · Dermatitis, Atopic (1) · Eczema (1) · Ichthyosis Bullosa of Siemens (1) · Intellectual Disability (1) · Irritable Bowel Syndrome (1) · Muscle Spasticity (1) · Retinal Diseases (1) · Sjogren-Larsson Syndrome (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Genetic (1)
Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Infant, Newborn, Diseases (8) · Keratosis (8) · Skin Abnormalities (8) · Skin and Connective Tissue Diseases (8) · Skin Diseases (7) · Skin Diseases, Genetic (7) · Abnormalities, Multiple (6) · Ichthyosiform Erythroderma, Congenital (6) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Brain Damage, Chronic (1)
ADX-629 (1) · Glucagon-Like Peptide 1 (1) · WAS protein, human (1) · glucagon-like peptide (7-37), valyl(10)- (1) · pimecrolimus (1)
Daiichi Sankyo (2) · Azitra Inc. (1) · Children's Hospital of Philadelphia (1) · Mayo Clinic (1) · Novartis Pharmaceuticals (1) · Sixera Pharma (1) · University of Nebraska (1)
United States (7) · Austria (1) · France (1) · Germany (1) · Netherlands (1) · Sweden (1)
Albert C Yan, MD (1) · Maarten de Chateau, MD PhD (1) · Mary Spellman, MD (1) · Michael Camilleri, MD (1) · William B Rizzo, MD (1)
UL1RR024150 (1)